DWTX

Dogwood Therapeutics Inc

1.03

Nov 04 • 3:59 PM ET -0.01 (-0.96%)

1.03

Aftermarket • 5:19 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Nov 03, 6:31 PMNo clear catalyst identified for DWTX 15% drop as shares rebound from lows

Peers: LXRX VRTX HRTX TNXP ENSC SCLX EPRX CNTB AXSM PCRX

| Held by: VXF IWC

Scroll to Statements

Index	-
Market Cap	39.38M
Enterprise Value	29.90M
Income	-36.04M
Sales	0.00M
Book/sh	2.03
Cash/sh	0.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	8
IPO	Dec 17, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.51
P/C	4.10
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.89
Current Ratio	3.89
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-8.95
EPS next Y	-0.72
EPS next Q	-0.15
EPS this Y	87.73%
EPS next Y	17.71%
EPS next 5Y	52.48%
EPS past 3/5Y	36.34% 25.53%
Sales past 3/5Y	- -
EPS Y/Y TTM	52.36%
Sales Y/Y TTM	-
EPS Q/Q	83.04%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-142.86% -

Insider Own	74.09%
Insider Trans	0.00%
Inst Own	11.27%
Inst Trans	1.08%
ROA	-40.68%
ROE	-47.77%
ROIC	-52.66%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.23%
SMA50	-35.29%
SMA200	-47.21%
Trades

Shs Outstand	33.63M
Shs Float	8.81M
Short Float	0.71%
Short Ratio	0.83
Short Interest	0.06M
52W High	7.04 -85.38%
52W Low	0.90 14.32%
Volatility	14.55% 10.03%
ATR (14)	0.14
RSI (14)	29.62
Beta	2.13
Rel Volume	1.64
Avg Volume	75.13K
Volume	123,435

Perf Week	-16.94%
Perf Month	-32.24%
Perf Quarter	-41.14%
Perf Half Y	-37.58%
Perf YTD	-75.24%
Perf Year	-81.99%
Perf 3Y	-94.27%
Perf 5Y	-99.24%
Perf 10Y	-
Recom	1.00
Target Price	13.50
Prev Close	1.04
Price	1.03
Change %	-0.96%

Oct-19-26 08:30AM	Dogwood Announces $5 Million Private Placement with CK Life Sciences Int'l., (Holdings) Inc. (GlobeNewswire)
Oct-06-26 08:45AM	Dogwood to Participate in the 2026 Maxim Growth Summit (GlobeNewswire)
Sep-14-26 08:45AM	Dogwood Announces Completion of Enrollment in Ongoing Halneuron Phase 2b Trial (GlobeNewswire)
Aug-17-26 08:30AM	Dogwood to Host Virtual KOL Event to Discuss Halneuron for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 (GlobeNewswire)
Aug-13-26 08:30AM	Dogwood Therapeutics Announces Second Quarter 2026 Financial Results (GlobeNewswire)
08:30AM	Loading…
Jul-20-26 08:30AM	Dogwood Enrolls First 200 Patients in Ongoing Halneuron Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026 (GlobeNewswire)
Jun-30-26 08:45AM	Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board (GlobeNewswire) -9.55%
May-18-26 08:45AM	Dogwood Therapeutics Announces Commencement of Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study (GlobeNewswire) -7.10%
May-14-26 08:30AM	Dogwood Therapeutics Announces First Quarter 2026 Financial Results (GlobeNewswire) +6.45%
May-07-26 08:30AM	Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026 (GlobeNewswire) -5.45%
Apr-23-26 09:00AM	Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M (GlobeNewswire) -8.50%
Apr-15-26 09:00AM	Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy (GlobeNewswire)
Mar-18-26 08:30AM	Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) -7.76%
Feb-02-26 08:30AM	Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron Phase 2b Trial, Top Line Results Anticipated in Q3 2026 (GlobeNewswire) +5.02%
Jan-12-26 08:30AM	Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron Through Phase 2b Development (GlobeNewswire) +5.61%
10:15AM	Loading…
Dec-22-25 10:15AM	Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain (GlobeNewswire) -24.96%
Dec-02-25 08:00AM	Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 (ACCESSWIRE)
Nov-11-25 08:45AM	Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 (ACCESSWIRE)
Nov-06-25 08:45AM	Dogwood Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire) -6.47%
Oct-30-25 09:15AM	Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025 (ACCESSWIRE) +7.78%
Oct-14-25 08:45AM	Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025 (ACCESSWIRE)
Oct-07-25 08:45AM	Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron Pain Research Program at the 19th Annual Pain Therapeutics Summit (ACCESSWIRE)
Sep-29-25 07:15AM	Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients (GlobeNewswire) +43.30%
Sep-03-25 09:15AM	Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 09:00AM	Dogwood Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-07-25 01:08PM	Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron Phase 2b Trial (GlobeNewswire)
Aug-06-25 09:15AM	Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025 (GlobeNewswire)
Jun-10-25 07:30AM	Sidoti Events, LLC's Virtual June Small-Cap Conference (ACCESSWIRE)
Jun-03-25 09:15AM	Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference (GlobeNewswire) +6.26%
May-08-25 09:00AM	Dogwood Therapeutics Announces First Quarter 2025 Financial Results (GlobeNewswire)
08:30AM	Loading…
May-01-25 08:30AM	Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
Apr-11-25 09:15AM	Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance (GlobeNewswire)
Apr-03-25 09:00AM	Dogwood Therapeutics, Inc. Regains Nasdaq Compliance (GlobeNewswire)
Mar-31-25 03:45PM	Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -11.17%
Mar-18-25 08:45AM	Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy-Induced Neuropathic Pain (GlobeNewswire) -6.90%
Mar-14-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -20.83%
Mar-13-25 09:00AM	Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -27.76%
Mar-12-25 08:30AM	Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward (GlobeNewswire)
Jan-21-25 09:15AM	Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 (GlobeNewswire) +68.45%
Nov-18-24 08:45AM	Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study (GlobeNewswire) -37.71%
Nov-08-24 02:35AM	Q3 2024 Dogwood Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM	Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ... (GuruFocus.com)
Nov-07-24 07:05AM	Dogwood Therapeutics Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 09:15AM	Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 (GlobeNewswire)
Oct-30-24 09:15AM	Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.73%
Oct-08-24 08:29AM	Virios Therapeutics Transforms into Dogwood Therapeutics (TipRanks) +12.40%
Oct-07-24 07:05AM	Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: DWTX ) (GlobeNewswire) -18.50%
Aug-08-24 09:15AM	Virios Therapeutics Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 09:41AM	Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
Jul-23-24 09:15AM	Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center (GlobeNewswire) +6.70%
May-22-24 01:30PM	Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire) +10.83%
May-20-24 02:19PM	Top Midday Decliners (MT Newswires) -43.94%
10:25AM	Red Lobster Bankruptcy: What Happened to the Popular Seafood Chain? (InvestorPlace)
09:20AM	Why Is Virios Therapeutics (VIRI) Stock Down 44% Today? (InvestorPlace)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
03:54AM	Virios Therapeutics Prices $1.7 Million Common Stock Offering (MT Newswires)
May-19-24 08:53PM	Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire)
May-17-24 04:10PM	Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study (GlobeNewswire) -8.96% -43.94%
May-13-24 10:49AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 07:45AM	Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -13.15%
May-02-24 09:15AM	Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 (GlobeNewswire)
Mar-26-24 09:15AM	Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID (GlobeNewswire) -8.45%
Feb-29-24 09:15AM	Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-28-24 09:15AM	Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones (GlobeNewswire)
Jan-22-24 09:00AM	Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID (GlobeNewswire) -40.27%
Jan-02-24 07:05AM	Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID (GlobeNewswire)
Nov-14-23 09:55AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 07:05AM	Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -10.54%
Nov-06-23 07:05AM	Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 (GlobeNewswire) +6.40%
Oct-12-23 07:05AM	Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023 (GlobeNewswire)
Sep-18-23 07:05AM	Virios Therapeutics Announces Termination of At-The-Market Sales Agreement (GlobeNewswire)
Sep-12-23 07:05AM	Virios Therapeutics CEO Greg Duncan to Present at the SHARE Series Investor Event on Monday, September 18, 2023 (GlobeNewswire)
Aug-15-23 07:48AM	VIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024 (Zacks)
Aug-14-23 07:05AM	Virios Therapeutics Announces Halt to At-The-Market Offering Sales (GlobeNewswire) +18.52%
Aug-12-23 09:40AM	Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 07:05AM	Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -31.21%
Aug-09-23 07:05AM	Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia (GlobeNewswire) -7.10%
Aug-03-23 04:05PM	Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (GlobeNewswire)
Jul-24-23 08:40AM	VIRI: Encouraging Results for IMC-2 in Long COVID (Zacks)
Jul-17-23 02:20PM	Virios Therapeutics Long COVID Combo Therapy Shows Improvements: Long-COVID Impacts 65M People (Benzinga) -20.25%
07:05AM	Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study (GlobeNewswire)
May-25-23 04:05PM	Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -9.70% +19.01%
May-16-23 10:26AM	VIRI: Ready to Move IMC-1 Into Phase 3 Program (Zacks Small Cap Research)
May-15-23 07:05AM	Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia (GlobeNewswire)
May-11-23 07:49AM	VIRI Stock Earnings: Virios Beats EPS Estimates (InvestorPlace) -6.96%
07:39AM	We're A Little Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Rate (Simply Wall St.)
07:05AM	Virios Therapeutics Announces First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 07:05AM	Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 (GlobeNewswire) +9.75%
Apr-25-23 01:07PM	Virios Therapeutics Shares Almost Double In Trading Session - Here's Why (Benzinga) +55.13%
Apr-24-23 04:15PM	Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia (GlobeNewswire) -8.03%
Mar-16-23 07:10AM	VIRI: Anticipating Update on IMC-1 Following End-of-Phase 2 Meeting with FDA (Zacks Small Cap Research)
Mar-14-23 07:05AM	Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-07-23 07:05AM	Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023 (GlobeNewswire) -14.32%
Feb-13-23 07:05AM	Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023 (GlobeNewswire)
Jan-05-23 07:00AM	Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program (GlobeNewswire) +10.93%
Dec-05-22 08:30AM	Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 (ACCESSWIRE)
Nov-29-22 07:05AM	Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase (Business Wire)
Nov-22-22 06:15AM	VIRI: Ready to Approach FDA with Phase 3 Plans (Zacks Small Cap Research)
Nov-14-22 07:05AM	Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update (Business Wire) -10.50%
Nov-03-22 07:05AM	Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022 (Business Wire)

Show Previous News

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Chairman & CEOMr. Gregory Duncan

CFOMs. Angela Walsh

Ph.D.Dr. R. Michael Gendreau M.D.

Founder & Member of Scientific Advisory BoardDr. William L. Pridgen M.D.

Senior Vice President of OperationsMr. Ralph D. Grosswald M.P.H.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DWTX

Dogwood Therapeutics Inc

Upgrade your Finviz experience